antidepressant agent 1

Antidepressant agent 1, a pyrazidole-halogeno-derivative, exhibits antidepressant effects and can also be used to increase body temperature.

Antiulcer Agent 1 is an orally administered derivative of 2-(3,4-dimethoxyphenyl)ethylamine.

Antidepressant agent 5 is a 7-substituted tetrahydroisoquinoline derivative with antidepressant activity.Antidepressant agent 5 acts similarly to magnoflorine in the study of depression and can be used for the prevention and treatment of depressive disorders.

Acetic acid, 2-[4-[(2-ethyl-3-benzofuranyl)carbonyl]phenoxy]- is a compound used for antiviral activity determinations.

Anxiolytic/nonsedative agent-1 (TCS 1205) is a potent and selective GABAA agonist. Anxiolytic/nonsedative agent-1 shows appreciable affinity for the BzR in bovine brain membranes with Kis of 14, 121, 239 nM for α1β2γ2, α2β2γ2, α5β3γ2, respectively. Anxiolytic/nonsedative agent-1 shows α2 selective efficacy in vitro and anxioselective effects in vivo.

Anti-TB agent 1 is a potent and orally active anti-tuberculosis compound (MICs: < 2 nM against the Mtb strains H37Rv, rRMP, and rINH).

ethyl 2-[3,5-bis(trifluoromethyl)phenyl]-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylate is a synthetic compound belonging to the curcumin family. It is involved in the regulation of immune response and inflammation through inhibition of the NF-κB signaling pathway, in the regulation of antioxidant response through activation of the Nrf2 signaling pathway, and in the regulation of cell survival and proliferation through inhibition of the Akt signaling pathway.

Anticonvulsant agent 1 is a chemical compound with potent anticonvulsant properties.

GABAA receptor agent 1 has strong anticonvulsant activity and is a high affinity ligand of GABAA receptor.

Antimalarial agent 1 is an effective antimalarial agent.

Antitrypanosomal agent 1 is a potent and selective trypanothione reductase (TR) inhibitor (IC50: 3.3 μM) that also inhibits glutathione reductase (IC50: 64.8 μM) and T. brucei (EC50: 1 μM).

Antidepressant agent 4, an orally active compound, demonstrates efficacy as an antidepressant with additional anxiolytic, performance-enhancing, and nootropic activities [1].

Antidepressant agent 3, an orally active compound, showcases multifaceted pharmacological properties including antidepressant, anxiolytic, performance-enhancing, and nootropic activities [1].

Anti-Trypanosoma cruzi agent-1 (Compd E5) demonstrates a potent anti-Toxoplasma effect.

Anti-neurodegeneration agent 1, a neurodegeneration-targeting agent.

Antileishmanial agent-1 demonstrates activity against both L. amazonensis promastigotes (IC 50 = 15.52 μM) and intracellular amastigotes (IC 50 = 4.10 μM).

Anti-MRSA agent 1 is an MRSA inhibitor with an MIC value of 0.5 μg/mL and is effective in alleviating the effects of MRSA resistance.

Anti-melanoma agent 1 (Compound 5m) is an apoptotic inducer in melanoma cells.

Analgesic agent-1 is a potent analgesic that exhibits significant analgesic activity.

Anti-TSWV agent 1 is a highly effective inactivator (EC50:144 μg/mL) of tomato spotted wilt virus (TSWV).

Anti-osteoporosis agent-1 (comp 4aa) is a potent RPA (replication protein A) inhibitor with an IC50 value of 18 μM [1].

Anti-aging agent 1 (compound 24), a piperlongumine (PL) derivative, demonstrates a significant enhancement in senolytic activity, being 50 times more effective against senescent WI-38 fibroblasts than PL [1].

Hepatoprotective agent-1 (compound 1b) functions as a hepatoprotective agent, exhibiting anti-inflammatory, antiapoptotic, and antifibrotic effects [1].

Anti-amyloid agent-1 is a potent compound that inhibits amyloid aggregation, offering a promising approach for research into the treatment of amyloidosis [1].

Compound 3l, a paclitaxel derivative known as Microtubule Stabilizing Agent-1, effectively enhances tubulin polymerization and demonstrates antitumor efficacy [1].

Lipid-lowering agent-1 is a potent lipid-lowering compound that significantly inhibits the pharmacological effects of low-density lipoprotein cholesterol (LDLC) and promotes high-density lipoprotein cholesterol (HDLC) production. In rats on a high-fat diet, it substantially reduces fat.

Anti-Heart Failure Agent 1 is an orally available compound suitable for treating heart failure without causing vomiting, nausea, or restlessness.

Anti-inflammatory agent 1 is a chemical compound designated for reducing inflammation, structurally characterized by a [carboxyl acid], [oxygen], and [hydrocarbon] ring, with notable efficacy in mitigating inflammatory responses.

Anti-hyperglycemic agent 1 is a potent inhibitor of alpha-glucosidase (IC50: 0.53 μM). anti-Hyperglycemic agent 1 can be used to study diabetes.

Bronchospasmolytic agent 1 is a flutropium bromide compound and acts as a bronchospasmolytic agent.

Antiplatelet agent 1 is a ticagrelor analogue that exhibits anti-platelet effects and can be used in platelet agglutination studies.

Anti gram-positive negative bacteria agent 1 is an antibiotic conjugated with a synthetic MECAM-based siderophore, designed to combat both gram-positive and gram-negative bacteria.

Compound 11, labeled as a weak Hepatoprotective agent-1, is a naturally occurring substance extracted from the fruits of Arctium lappa L. It demonstrates modest hepatoprotective effects when applied at a concentration of 10 μM [1].

Therapeutic Agent-1, a heteroaryl compound, serves as an enzyme replacement therapy to enhance glucocerebrosidase activity in the treatment of Gaucher disease [1].

Herbicidal agent 1 ((S)-6q) exhibits superior activity compared to its racemic form [1].

Anabolic agent-1 is a novel bone morphogenetic protein-2 up regulator, with the capability of rectifying bone loss in patients and exhibiting versatile clinical applicability.

Pulmonary arterial hypertension agent-1 (example 15), recognized as a click chemistry reagent in [1], includes an Alkyne group that facilitates copper-catalyzed azide-alkyne cycloaddition (CuAAc) with Azide group-containing molecules. This compound is utilized specifically for treating pulmonary arterial hypertension.

Anti-NASH Agent 1 (Compound 3d), derived from Elafibranor, serves as a strong PPAR-α/δ agonist aimed at treating nonalcoholic steatohepatitis (NASH). At dosages of 3-10 mg/kg over four weeks, this compound ameliorates hyperlipidemia, liver fat degeneration, and inflammation in a methionine-choline deficiency (MCD)-induced NASH mouse model, exhibiting minimal hepatotoxicity while providing substantial hepatic protection [1].

Hypoglycemic agent 1 has an action for lowering blood sugar. It acts as a therapeutic and/or prophylactic agent for diabetes.

Anti-infective agent 1 (compound 3a) serves as a potent and selective antiprotozoal and antimycobacterial compound, demonstrating antiparasitic efficacy against P. falciparum and T. brucei rhodesiense with IC50 values of 10.95 and 0.06 μM, respectively, and displaying antimycobacterial properties against Mycobacterium smegmatis with a minimum inhibitory concentration (MIC) of 8 μg mL [1].

Antiallergic agent-1, an Src family kinase inhibitor, is a new and valuable lead compound with potential as an anti-allergic agent.

Anti-virus agent 1 (compound 4i), a phosphoramidate prodrug of GS-5734, exhibits potent antiviral efficacy and is primarily utilized in coronavirus and Ebola virus (EBOV) research.

Antioxidant anticancer agent 1 (compound 5) is a Schiff base derivative of pyrimidine and pyrimidine hydroxy-1-naphthaldehyde, exhibiting antibacterial, antioxidant, antifungal, and anticancer properties [1].

Antituberculosis Agent-1 (Compound 8a) is an effective antituberculosis agent, demonstrating a minimum inhibitory concentration (MIC) of 3.84 μg/mL against Mycobacterium tuberculosis H37Rv [1].

Apoptotic agent-1 (Compound 8a) induces over-expression of the Fas receptor and Cyto C genes, exhibiting high antiproliferative activity against cancer cells and low cytotoxic effects [1].

Anti-IAV Agent 1-1a is an orally administered compound effective against the Influenza A virus (IAV), demonstrating inhibitory concentration 50 (IC50) values of 0.03 μM and 0.06 μM for the H1N1 strain and the Oseltamivir-resistant H1N1 strain of IAV, respectively.

Antiarrhythmic agent-1 (example I), functioning as an antiarrhythmic agent and an IKr potassium channel blocker (IC 50 <1 μM), effectively inhibits cardiac arrhythmias.

Antitubulin Agents-1, an antitubulin agent, disrupts microtubules (Microtubule/Tubulin) and enhances α-tubulin acetylation, exhibiting anticancer effects.

Phototherapeutic agent-1, a multi-modal diagnostic agent with aggregation-induced emission properties, possesses the capacity to generate reactive oxygen species (ROS) under illumination. This capacity enables Phototherapeutic agent-1 to effectively eliminate cancer cells and tumor tissue [1].

Antistaphylococcal agent 1 is an antistaphylococcal therapeutic agent [antistaphylococcal agent 1].